Dr Maha Hussain at the recent virtual ASCO Meeting. Credit: ASCO Second look analysing prostate cancer study data reaps new rewards Two studies unveiled at last month’s virtual Genitourinary Cancers Symposium, organised by the American Society of Clinical Oncology, will have implications for both the treatment of prostate cancer and the provision of screening, Peter Doyle reports In men with non-metastatic castration-resistant prostate cancer (nmCRPC) and rapidly rising prostate specific antigen (PSA) treated with androgen deprivation therapy (ADT) plus enzalutamide (ENZA), there was a close relationship between the degree of PSA decline and survival outcomes, according to a newly published post-hoc analysis of the PROSPER trial.